ALLK Allakos Inc.

37.68
+2.52  (+7%)
Previous Close 35.16
Open 35.54
Price To Book 8.1
Market Cap 1586820063
Shares 42,113,059
Volume 304,663
Short Ratio
Av. Daily Volume 365,219

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due late 1Q/Early 2Q 2019.
AK002
Severe Allergic Conjunctivitis
Phase 1 data released February 19, 2019.
AK002
Indolent Systemic Mastocytosis
Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
AK002
Chronic Urticaria
Phase 2 top-line data due mid-2019.
AK002
Eosinophilic Gastritis

SEC Filings

  1. 8-K - Current report 19614332
  2. 8-K - Current report 19613467
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19599266
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 19594510
  5. 8-K - Current report 19581942
  6. 8-K - Current report 19561655
  7. 8-K - Current report 19547153
  8. 8-K - Current report 19512230
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170244
  10. 8-K - Current report 181169675